Shire plc (SHP.L)

LSE - LSE Delayed Price. Currency in GBp
5,120.00-88.00 (-1.69%)
At close: 12:11 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5,208.00
Bid5,100.00 x 51000
Ask5,160.00 x 53800
Day's Range5,105.00 - 5,197.00
52wk Range2,707.19 - 5,562.83
1y Target EstN/A
Market Cap45.84B
P/E Ratio (ttm)31.92
Avg Vol (3m)2,034,728
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Billionaire James Dinan’s York Capital Initiated Stakes in These Companies
    Insider Monkey10 hours ago

    Billionaire James Dinan’s York Capital Initiated Stakes in These Companies

    Though billionaire James Dinan‘s York Capital Management manages regulatory assets worth over $25 billion, its latest 13F filing reveals that less than 16% of it or only $4 billion was invested in US equities at the end of second quarter. The New York-based hedge fund that will be celebrating its silver jubilee this year manages […]

  • Reuters3 days ago

    Shire raises eyebrows with stunning debut

    Investors piled into the debut bond from Shire this week, ignoring some clear warning signals that the drugmaker's deal might have offered a little bit less than meets the eye. The US$12.1bn trade amassed a US$28.5bn order book, even as analysts were noting that Shire's debt-to-Ebitda ratio had jumped from less than one time to more than seven times in 12 months. Proceeds will help finance Shire's US$32bn hostile takeover of rival Baxalta, and some of the buyside demand could be put down to investor appetite for all things pharma.

  • PR Newswire3 days ago

    Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting

    Shire plc (LSE: SHP, NASDAQ: SHPG) will showcase data across its global leading immunoglobulin (IG) portfolio during the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID), taking place September 21-24, 2016 in Barcelona. Presentations will include results of studies examining the safety, efficacy and tolerability profiles of Shire's IG treatment options for immune deficiencies, including primary immunodeficiency (PI). Shire will complement the data on treatment options with research on the burden PI patients experience relating to their disease and treatment, as part of Shire's commitment to delivering advanced, individualized treatment options for people with PI.